NUCANA PLC-ADR (NCNA) Stock Price, Quote, News and Overview
NASDAQ:NCNA - Nasdaq - US67022C2052 - ADR - Currency: USD
NCNA Quote, Performance and Key Statistics
1.09
+0.03 (+2.83%)
The current stock price of NCNA is 1.09 USD. In the past month the price decreased by -0.91%. In the past year, price decreased by -85.94%.
NCNA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About NCNA
Company Profile
NuCana PLC is a GB-based company operating in Biotechnology industry. NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The firm is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The firm's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The firm is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Company Info
NUCANA PLC-ADR
Lochside House, 3 Lochside Way
Edinburgh EH12 9DT GB
CEO: Hugh Griffith
Employees: 27
Company Website: https://www.nucana.com/
Investor Relations: https://ir.nucana.com/news-releases
Phone: 4401313571111
NUCANA PLC-ADR / NCNA FAQ
What is the stock price of NUCANA PLC-ADR today?
The current stock price of NCNA is 1.09 USD. The price increased by 2.83% in the last trading session.
What is the ticker symbol for NUCANA PLC-ADR stock?
The exchange symbol of NUCANA PLC-ADR is NCNA and it is listed on the Nasdaq exchange.
On which exchange is NCNA stock listed?
NCNA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NUCANA PLC-ADR stock?
8 analysts have analysed NCNA and the average price target is 25.5 USD. This implies a price increase of 2239.45% is expected in the next year compared to the current price of 1.09. Check the NUCANA PLC-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NUCANA PLC-ADR worth?
NUCANA PLC-ADR (NCNA) has a market capitalization of 2.47M USD. This makes NCNA a Nano Cap stock.
How many employees does NUCANA PLC-ADR have?
NUCANA PLC-ADR (NCNA) currently has 27 employees.
What are the support and resistance levels for NUCANA PLC-ADR (NCNA) stock?
NUCANA PLC-ADR (NCNA) has a resistance level at 1.21. Check the full technical report for a detailed analysis of NCNA support and resistance levels.
Should I buy NUCANA PLC-ADR (NCNA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NCNA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NCNA, evaluating the profitability, health, valuation and growth aspects
- NUCANA PLC-ADR (NCNA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NUCANA PLC-ADR (NCNA) Sales and EPS estimates to see what analysts future expectations are.
- NUCANA PLC-ADR (NCNA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NUCANA PLC-ADR (NCNA) Insider and Institutional Ownership to learn about the owners and their transactions.
- NUCANA PLC-ADR (NCNA) Stock Chart to make your own analysis
- NUCANA PLC-ADR (NCNA) Latest news and press-releases to stay up to date.
Does NUCANA PLC-ADR (NCNA) stock pay dividends?
NCNA does not pay a dividend.
When does NUCANA PLC-ADR (NCNA) report earnings?
NUCANA PLC-ADR (NCNA) will report earnings on 2025-03-18, after the market close.
What is the Price/Earnings (PE) ratio of NUCANA PLC-ADR (NCNA)?
NUCANA PLC-ADR (NCNA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.54).
What is the Short Interest ratio of NUCANA PLC-ADR (NCNA) stock?
The outstanding short interest for NUCANA PLC-ADR (NCNA) is 2.37% of its float. Check the ownership tab for more information on the NCNA short interest.
NCNA Technical Analysis
NCNA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NCNA. NCNA may be in some trouble as it scores bad on both profitability and health.
NCNA Financial Highlights
Over the last trailing twelve months NCNA reported a non-GAAP Earnings per Share(EPS) of -14.54. The EPS increased by 31.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -140.43% | ||
| ROE | -741.68% | ||
| Debt/Equity | 0.04 |
NCNA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to NCNA. The Buy consensus is the average rating of analysts ratings from 8 analysts.